CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Mobile app follow-up care +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02318953
NCT02318953N/ACompleted

The Effect of Mobile App Home Monitoring on the Number of In-Person Visits Following Ambulatory Surgery: A Randomized Control Trial

Women's College Hospital·interventional·Posted Dec 17, 2014·Updated Oct 7, 2015

In Brief

A clinical study evaluating Mobile app follow-up care and Conventional, in-person follow-up care for Use of Mobile App Home Monitoring After Ambulatory Surgery. Completed, enrolled 70 participants across 1 site.

Detailed Summary

This study evaluate if in an ambulatory breast reconstruction patient population at Women's College Hospital (WCH), can we avert in-person follow-up care through the use of mobile app home monitoring compared to conventional, in-person follow-up care in the first 30-days following surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 17, 2014
Enrollment StartJan 1, 2015
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.5 years ago

Interventions

Mobile app follow-up caredevice

The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.

Conventional, in-person follow-up careother

This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.